Physician profile
John Evans
NPI 1316395601
$9,776.77
in general payments reported to CMS, 2019-2025
30 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $243 · 2021: $705 · 2022: $467 · 2023: $4,679 · 2024: $1,578 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,550 · Consulting Fee: $2,800 · Travel and Lodging: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,549.87 |
| Consulting Fee | $2,800.00 |
| Travel and Lodging | $882.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,326.53 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $904.83 | 2021-2025 | |
| Abbvie INC. | $695.80 | 2020-2025 | |
| Genzyme Corporation | $503.93 | 2021-2025 | |
| Ucb, INC. | $393.31 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $364.12 | 2020-2025 | Nemluvio, Aklief, Epsolay |
| Lilly USA, LLC | $306.22 | 2020-2025 | Taltz, Ebglyss |
| Pfizer INC. | $295.90 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $270.10 | 2020-2024 | Targretin, Siliq, Duobrii |
| Janssen Biotech, INC. | $266.34 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $226.85 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $169.50 | 2021-2025 | Dupixent |
| Dermavant Sciences, INC. | $167.88 | 2023-2024 | Vtama |
| Amgen INC. | $152.34 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $135.13 | 2022-2025 | Adbry, Anzupgo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $100.03 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $93.92 | 2022-2024 | Xtrac |
| Mayne Pharma Commercial LLC | $57.51 | 2025 | |
| Verrica Pharmaceuticals INC. | $53.87 | 2023-2025 | Ycanth |
| Kyowa Kirin, INC. | $52.34 | 2020-2021 | |
| Organon LLC | $43.93 | 2025 | Vtama |
| Organogenesis INC. | $40.86 | 2024-2025 | Novachor, Cygnus Dual |
| Incyte Corporation | $26.03 | 2025 | Opzelura |
| Dermira, INC. | $25.37 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.08 | 2025 | Spevigo |
| Convatec INC. | $19.21 | 2025 | |
| Urgo Medical North America, LLC | $18.88 | 2025 | Urgoclean Ag |
| Arcutis Biotherapeutics, INC. | $16.83 | 2025 | Zoryve |
| Medline Industries Lp | $14.17 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.